hydroxychloroquine has been researched along with Lymphoma, B-Cell in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The 4-aminoquinolines, including chloroquine and hydroxychloroquine, have been successfully employed to treat patients with granuloma-forming disease-associated, vitamin D metabolite-mediated hypercalcemia." | 7.70 | Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. ( Adams, JS; Kantorovich, V, 1999) |
| "The 4-aminoquinolines, including chloroquine and hydroxychloroquine, have been successfully employed to treat patients with granuloma-forming disease-associated, vitamin D metabolite-mediated hypercalcemia." | 3.70 | Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. ( Adams, JS; Kantorovich, V, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mezzaroba, N | 1 |
| Zorzet, S | 1 |
| Secco, E | 1 |
| Biffi, S | 1 |
| Tripodo, C | 1 |
| Calvaruso, M | 1 |
| Mendoza-Maldonado, R | 1 |
| Capolla, S | 1 |
| Granzotto, M | 1 |
| Spretz, R | 1 |
| Larsen, G | 1 |
| Noriega, S | 1 |
| Lucafò, M | 1 |
| Mansilla, E | 1 |
| Garrovo, C | 1 |
| Marín, GH | 1 |
| Baj, G | 1 |
| Gattei, V | 1 |
| Pozzato, G | 1 |
| Núñez, L | 1 |
| Macor, P | 1 |
| Adams, JS | 1 |
| Kantorovich, V | 1 |
2 other studies available for hydroxychloroquine and Lymphoma, B-Cell
| Article | Year |
|---|---|
New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Autophagy; Cell Survival | 2013 |
Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cyclophosphamide; Doxorubic | 1999 |